HGF2.F · Catalyst Biosciences, Inc

-

Please sign in to comment on HGF2.F

1 Comment

Admin

4 years ago

Catalyst Biosciences, Inc is currently in a long term downtrend where the price is trading 21.6% below its 200 day moving average.

From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.6.

Catalyst Biosciences, Inc's total revenue rose by inf% to $2M since the same quarter in the previous year.

Its net income has dropped by 38.9% to $-19M since the same quarter in the previous year.

Finally, its free cash flow fell by 173.9% to $-22M since the same quarter in the previous year.

Based on the above factors, Catalyst Biosciences, Inc gets an overall score of 2/5.

Industry	Biotechnology
Sector	Healthcare
Exchange	F
CurrencyCode	EUR
ISIN	US14888D2080

PE Ratio	None
Target Price	16.6
Market Cap	19M
Beta	1.29
Dividend Yield	None

ABOUT

Catalyst Biosciences, Inc

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

HGF2.F · Catalyst Biosciences, Inc

-

Catalyst Biosciences, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Catalyst Biosciences, Inc using a moving average strategy